Recurrent Small Cell Lung Cancer (SCLC) Terminated Phase 2 Trials for Rebeccamycin (DB14729)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Small Cell Lung Cancer Recurrent / Refractory Small cell lung cancer / Recurrent Small Cell Lung Cancer / Recurrent Lung Small Cell Carcinoma / Recurrent Small Cell Lung Carcinoma

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00084487Rebeccamycin Analog as Second-Line Therapy in Treating Patients With Limited-Stage or Extensive-Stage Small Cell Lung Cancer That Relapsed After Previous First-Line ChemotherapyTreatment